What was the most common adverse reaction reported with golimumab in pivotal clinical trials?

Upper respiratory tract infection was the most common adverse reaction during the controlled period of pivotal golimumab trials in RA, PsA, AS, nr-Axial SpA and UC, occurring in 12.6% of golimumab-treated patients versus 11.0% of controls.